NCT06090331 is a clinical trial of 89Zr-DFO-girentuximab in Clear Cell Renal Cell Carcinoma, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.

Who is sponsoring NCT06090331?

NCT06090331 is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.

What drugs are being tested in NCT06090331?

Interventions in NCT06090331: 89Zr-DFO-girentuximab.

What condition does NCT06090331 study?

NCT06090331 studies Clear Cell Renal Cell Carcinoma.

Is NCT06090331 still recruiting?

NCT06090331 is currently available. Last updated 8 July 2025.

Last reviewed 2025-07-08 · How we verify

NCT06090331

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

89Zr-DFO-girentuximab Expanded Access Program (EAP)

AVAILABLE Last updated 8 July 2025

What this trial tests

trial testing 89Zr-DFO-girentuximab in Clear Cell Renal Cell Carcinoma. Available.

Quick facts

Lead sponsor	Telix Pharmaceuticals (Innovations) Pty Limited
Status	AVAILABLE
Study type	EXPANDED_ACCESS
Sites	17 locations across United States

Drugs / interventions tested

89Zr-DFO-girentuximab — full drug profile →

Conditions studied

Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →

Sponsor

Telix Pharmaceuticals (Innovations) Pty Limited — full company profile →

Who can join

Adults 18 to 99, any sex, with Clear Cell Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Ferroptosis in Renal Cancer Therapy: A Narrative Review of Drug Candidates.
Yu L, Qiu Y, Tong X. · · 2024 · cited 7× · PMID 39335103 · DOI 10.3390/cancers16183131
<sup>89</sup>Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma.
Cao Y, Kim J, Talluto J, McVeigh T, et al · · 2026 · PMID 41754999 · DOI 10.3390/pharmaceutics18020258
89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma
Cao Y, Kim J, Talluto J, McVeigh T, et al · · 2026

Verify or expand the search:

Other trials of 89Zr-DFO-girentuximab

Trials testing the same drug.

NCT07179770 — Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) · Phase 1 · recruiting

Other recruiting trials for Clear Cell Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07187778 — Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal · Phase 2 · recruiting
NCT07389629 — Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting

Other Telix Pharmaceuticals (Innovations) Pty Limited trials

Trials by the same sponsor.

NCT07197580 — Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC · Phase 3 · recruiting
NCT07197645 — Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain · Phase 1 · recruiting
NCT07238322 — [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes · active not recruiting
NCT06655064 — Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations · terminated
NCT06750419 — 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06090331 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Telix Pharmaceuticals (Innovations) Pty Limited
Last refreshed: 8 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06090331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing